Claims for Patent: 10,539,574

Summary for Patent: 10,539,574

Title:	Identity and purity of tissue biopsies
Abstract:	A method for the in vitro detection of cartilage tissue and/or for the in vitro determination of the purity of cartilage tissue includes: a) treating a tissue sample with a protease and b) testing the protease-treated tissue sample for the presence of protease-resistant fragments of type II collagen and/or type I collagen. Methods can be carried out for preparing a cartilage cell culture, and for preparing a cartilage cell-loaded implant. Protease-resistant fragments of type II collagen and/or type I collagen can be used for the in vitro detection of cartilage tissue and/or for the in vitro determination of the purity of cartilage tissue. A kit can be used for carrying out the methods.
Inventor(s):	Benz; Karin (Goppingen, DE), Freudigmann; Christian (Reutlingen, DE), Gaissmaier; Christoph (Kusterdingen, DE), Hecky; Jochen (Freiburg, DE), Mollenhauer; Jurgen (Reutlingen, DE)
Assignee:	TETEC Tissue Engineening Technologies AG (Reutlingen, DE)
Application Number:	15/324,076
Patent Claims:	1. A method for the in vitro determination of the degree of purity of cartilage tissue, comprising the following steps: a) treating a tissue sample with a protease and b) testing the protease-treated tissue sample for the presence of protease-resistant fragments of type II collagen and type I collagen, wherein the degree of purity of the tissue sample with regard to cartilage tissue present therein is ascertained by calculating percentage of the protease-resistant fragments of type II collagen and type I collagen within the tissue sample wherein the tissue sample is a cartilage biopsy or a fragment thereof, wherein the protease-resistant fragments of type II collagen are C-terminal crosslinked type II collagen telopeptides (CTX-II) or fragments thereof and wherein the protease-resistant fragments of type I collagen are N-terminal crosslinked type I collagen telopeptides (NTX-I) or fragments thereof. 2. The method as claimed in claim 1, wherein the tissue sample is a joint biopsy. 3. The method as claimed in claim 1, wherein superficial cartilage tissue, mineralized cartilage tissue and/or bone tissue is removed from the tissue sample before step a) is carried out. 4. The method as claimed in claim 1, wherein the protease is collagenase. 5. The method as claimed in claim 1, wherein the protease-resistant fragments of type II collagen and/or type I collagen have crosslinks selected from the group comprising allysine crosslinks, hydroxyallysine crosslinks, dehydrohydroxylysinonorleucine crosslinks, dehydrolysinonorleucine crosslinks, hydroxylysino-5-ketonorleucine crosslinks, dihydroxylysinonorleucine crosslinks, hi stidinohydroxylysinonorleucine crosslinks, hydroxylysylpyridinoline crosslinks, lysylpyridinoline crosslinks, pyridinium crosslinks, 3-hydroxypyridinium crosslinks, histidinohydroxymerodesmosine crosslinks and combinations thereof. 6. The method as claimed in claim 1, wherein step b) is carried out by contacting the protease-treated tissue sample with an antibody or antibody fragment, the antibody or the antibody fragment being specifically directed against protease-resistant fragments of type II collagen. 7. The method as claimed in claim 1, wherein step b) is carried out by contacting the protease-treated tissue sample with an antibody or antibody fragment, the antibody or the antibody fragment being specifically directed against protease-resistant fragments of type I collagen. 8. The method as claimed in claim 6, wherein an immunological technique is used to detect the binding of the antibody or antibody fragment to the protease-resistant fragments. 9. A method for preparing a cartilage cell culture, comprising the following steps: a) treating a cartilage tissue sample with a protease, b) testing the protease-treated cartilage tissue sample for the presence of protease-resistant fragments of type II collagen and type I collagen, c) identifying and isolating cartilage cells from the tested protease-treated cartilage tissue sample, and d) culturing cartilage cells present in the tested cartilage tissue sample, wherein in step c), the cartilage cells are identified by ascertaining the degree of purity of the cartilage tissue by calculating percentage of the protease-resistant fragments of type II collagen and type I collagen within the tissue sample, and wherein the protease-resistant fragments of type II collagen are C-terminal crosslinked type II collagen telopeptides (CTX-II) or fragments thereof and wherein the protease-resistant fragments of type I collagen are N-terminal crosslinked type I collagen telopeptides (NTX-I) or fragments thereof. 10. A method for preparing a cartilage cell-loaded implant comprising the following steps: a) treating a cartilage tissue sample with a protease, b) testing the protease-treated cartilage tissue sample for the presence of protease-resistant fragments of type II collagen and type I collagen, c) identifying and isolating cartilage cells from the tested protease-treated cartilage tissue sample, d) culturing cartilage cells present in the tested cartilage tissue sample and e) loading an implant with the cultured cartilage cells, wherein in step c), the cartilage cells are identified by ascertaining the degree of purity of the cartilage tissue by calculating percentage of the protease-resistant fragments of type II collagen and type I collagen within the tissue sample, and wherein the protease-resistant fragments of type II collagen are C-terminal crosslinked type II collagen telopeptides (CTX-II) or fragments thereof and wherein the protease-resistant fragments of type I collagen are N-terminal crosslinked type I collagen telopeptides (NTX-I) or fragments thereof.

Details for Patent 10,539,574

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Smith & Nephew, Inc.	SANTYL	collagenase	Ointment	101995	06/04/1965		2034-07-11